• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Sci Rep . Role of IgG against N-protein of SARS-CoV2 in COVID19 clinical outcomes

tetano

Editor, Senior Moderator
Sci Rep


. 2021 Feb 10;11(1):3455.
doi: 10.1038/s41598-021-83108-0.
Role of IgG against N-protein of SARS-CoV2 in COVID19 clinical outcomes


Mayank Batra[SUP] 1 [/SUP], Runxia Tian[SUP] 1 [/SUP], Chongxu Zhang[SUP] 1 [/SUP], Emile Clarence[SUP] 2 [/SUP], Camila Sofia Sacher[SUP] 2 [/SUP], Justin Nestor Miranda[SUP] 2 [/SUP], Justin Rafa O De La Fuente[SUP] 2 [/SUP], Megan Mathew[SUP] 2 [/SUP], Desmond Green[SUP] 2 [/SUP], Sayari Patel[SUP] 2 [/SUP], Maria Virginia Perez Bastidas[SUP] 1 [/SUP], Sara Haddadi[SUP] 1 [/SUP], Mukunthan Murthi[SUP] 1 [/SUP], Miguel Santiago Gonzalez[SUP] 1 [/SUP], Shweta Kambali[SUP] 1 [/SUP], Kayo H M Santos[SUP] 1 [/SUP], Huda Asif[SUP] 1 [/SUP], Farzaneh Modarresi[SUP] 3 [/SUP], Mohammad Faghihi[SUP] 3 [/SUP], Mehdi Mirsaeidi[SUP] 4 [/SUP]



Affiliations

Abstract

The Nucleocapsid Protein (N Protein) of severe acute respiratory syndrome Coronavirus 2 (SARS-CoV2) is located in the viral core. Immunoglobulin G (IgG) targeting N protein is detectable in the serum of infected patients. The effect of high titers of IgG against N-protein on clinical outcomes of SARS-CoV2 disease has not been described. We studied 400 RT-PCR confirmed SARS-CoV2 patients to determine independent factors associated with poor outcomes, including Medical Intensive Care Unit (MICU) admission, prolonged MICU stay and hospital admissions, and in-hospital mortality. We also measured serum IgG against the N protein and correlated its concentrations with clinical outcomes. We found that several factors, including Charlson comorbidity Index (CCI), high levels of IL6, and presentation with dyspnea were associated with poor clinical outcomes. It was shown that higher CCI and higher IL6 levels were independently associated with in-hospital mortality. Anti-N protein IgG was detected in the serum of 55 (55%) patients at the time of admission. A high concentration of antibodies, defined as signal to cut off ratio (S/Co) > 1.5 (75 percentile of all measurements), was found in 25 (25%) patients. The multivariable logistic regression models showed that between being an African American, higher CCI, lymphocyte counts, and S/Co ratio > 1.5, only S/Co ratio were independently associated with MICU admission and longer length of stay in hospital. This study recommends that titers of IgG targeting N-protein of SARS-CoV2 at admission is a prognostic factor for the clinical course of disease and should be measured in all patients with SARS-CoV2 infection.
 
Back
Top Bottom